ABBV - AbbVie Inc. Charts, Trade Ideas, Earnings, Ratings

TRENDING : Top 50 AAPL (-0.7%) VXX (-1.63%) SPY (0.15%) ROKU (4.45%) DGAZ (4.4%) UGAZ (-3.81%) TWTR (-0.66%) TVIX (-2.37%) TTD (-0.34%) AAOI (-3.88%) A (-0.52%) SNAP (-0.7%) SBUX (0.53%) RVLV (-3.1%) CSCO (-7.33%) CHK (-1.69%) ALB (%) ACRE (%) PINS (%) MELI (%) LYFT (%) KOPN (%) KO (%) KIM (%) JNPR (%)

ABBV - AbbVie Inc.

$87.63 0.97[1.12%]

15 mins delayed data

People also watch : LLY | AZN | BIIB | NBIX | BMY | PFE

+Watchlist

11 StockHoot Traders following this.
Analyst Ratings | Earnings

Previous Close	$86.66	Open	$86.48
Volume	5.43M	Market Cap	125.981B
Yield	0.0502%	Last Dividend	$4.28

Day

52 Week

Seth Klarman Exits Allergan, Buys 3 New ...	3:24 PM
Baupost manager reports quarterly portfolio Continue reading...

Exicures shares up on Allergan partnersh...	5:28 AM
Shares of Exicure are up 26% in premarket trading on the news that the biotechnology company entered into an agreement with Allergan to develop trea...

Beware of Runs on Bond Funds	3:00 AM
In a less favorable market, however, bond fund investors could get hurt—not so much by worsening fundamentals, but the funds’ difficulty to meet redem...

AbbVie Sold $30 Billion in Bonds, and Tw...	2:01 AM
You may have heard that number cited recently as the value of an asteroid called 16 Psyche . If humans ever manage to mine the asteroid, a flood of s...

AbbVie Takes on Debt to Buy Allergan	11/13/19
The $30 billion corporate loan is intended to finance the acquisition of Allergan Continue reading...

AbbVie’s $30 Billion Bond Sale Was Wall ...	11/13/19
Investors were willing to pay up on Tuesday to buy the fourth-biggest corporate bond sale on record. To finance the acquisition, AbbVie sold $30 billi...

Abbott Labs Chooses an Insider to Be Its...	11/13/19
Miles White, who has led the business since 1999, will be succeeded by Robert Ford, president and chief operating officer of the pharmaceutical and me...

Cash Stashes Dwindle as Markets Crest an...	11/13/19
Plus, we preview Wednesday's Trump-Erdogan meeting and check out AbbVie's huge debt offering as well as the new Abode-Microsoft connection.

AbbVie Prices $30 Billion of Senior Unse...	11/12/19
NORTH CHICAGO, Ill., Nov. 12, 2019 /PRNewswire/ -- AbbVie Inc. (ABBV) ("AbbVie") announced today that it has priced its previously announced private o...

AbbVie Sells $30 Billion of Bonds to Fun...	11/12/19
(Bloomberg) -- AbbVie Inc. sold $30 billion of bonds to help finance its acquisition of Allergan Plc as investors flocked to buy a piece of the larges...

US Indexes End the Day Higher Tuesday	11/12/19
S&P; 500 closes at 3,091.84 for a gain of 0.16% Continue reading...

ANALYST RATINGS

4 analyst ratings (Last 6 months)

75.00 %

Strong Buy + Buy

Price Target (PT)

Buy rating	09/12/19
UBS upgrades from Neutral to Buy rating and lowers Price Target from $85.00 to $79.00

Strong Buy rating	09/04/19
Piper Jaffray maintains Overweight rating and raises Price Target from $80.00 to $81.00

Strong Buy rating	08/20/19
Piper Jaffray upgrades from Neutral to Overweight rating and announces Price Target of $80.00

Hold rating	05/28/19
Goldman Sachs initiates coverage with Neutral rating and announces Price Target of $84.00

EARNINGS

Date	2019-11-01 (BMO)	Est. (EPS/Rev.)	$2.30/ 8.38B
Actual (EPS/Rev.)	$2.33/ $8.48 B	EPS (TTM)	2.18

TRADERS TRACKING $ABBV

Service Name	Trader	% Success
OptionIncome	random motion	95.00 %	Subscribe
Alpha Swing Trades	Jonathan	69.00 %	Follow
Growth Safe Bets	Hao	61.00 %	Subscribe
MA MA MIA	Hao	60.00 %	Subscribe
Market Focus	Hao	60.00 %	Subscribe

SHOW ALL TRADERS

About Us

Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.

Product Types

Strategies

Follow Us

Secure Payments

We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.